The research team, led by Qinghua Guo, Yong Wang, Chuan Shi, and Shaomei Shang, followed 136 adults undergoing an acute course of ECT in a real-world clinical setting. Each participant completed the ECT-CI and the Montreal Cognitive Assessment, better known as the MoCA, at three time points: before treatment began, within 48 hours after the acute course ended, and again at a three-month follow-up. Crucially, the study did not rely on test scores alone to define impairment. Blinded psychiatrists adjudicated whether each patient met criteria for cognitive impairment using a framework based on the DSM-5-TR, the current edition of the American Psychiatric Association’s diagnostic manual, and those clinician judgments served as the reference standard against which both instruments were judged.

The clinical picture that emerged was sobering. Clinician-adjudicated cognitive impairment rose from 12.5 percent of patients at baseline to 33.1 percent immediately after the acute treatment course, and then climbed further to 50.7 percent at the three-month follow-up. That trajectory, in which the proportion of patients judged cognitively impaired continues to rise well after the last seizure has been induced, underscores how incomplete our understanding of post-ECT cognition remains. Many patients do not simply recover in a straight line after treatment ends, and some appear to experience worsening difficulties that only become apparent weeks later, a pattern that brief in-hospital testing at discharge would entirely miss.

Against this backdrop, the performance of the two cognitive instruments diverged in ways that matter for everyday practice. ECT-CI scores fell from baseline to the post-course assessment and then partially rebounded at follow-up, and the magnitude of those observed score changes was larger than what the MoCA captured over the same period. The ECT-CI also took less time to administer, a nontrivial advantage at the bedside of acutely ill psychiatric inpatients. At the domain level, the inventory registered changes in memory, executive function, and caregiver-rated cognition, offering a multidimensional view of how patients were actually functioning rather than a single composite number. In statistical comparisons of discrimination, essentially the ability of a test score to separate patients who have impairment from those who do not, the ECT-CI outperformed the MoCA against the clinician-adjudicated reference standard at every assessment point.

Perhaps the most clinically consequential finding concerned prediction. Baseline ECT-CI scores showed greater prognostic discrimination than baseline MoCA scores for identifying which patients would meet the clinician-adjudicated criteria for cognitive impairment three months later. In practical terms, this means a brief test administered before the first seizure could help clinicians flag patients at elevated risk of lasting cognitive difficulty, opening a window for interventions that do not currently exist in routine care: closer monitoring, adjusted treatment parameters, or earlier supportive measures. The MoCA, designed as a general screen for dementia and delirium across clinical populations, simply was not built to detect the specific, often subtle cognitive signature that ECT produces.

To move beyond averages and capture the diversity of individual recovery patterns, the researchers turned to growth mixture modelling, a statistical technique that identifies hidden subgroups within a population based on how their scores change over time. The analysis revealed three distinct ECT-CI trajectories. One group maintained high, stable scores throughout, suggesting resilience to the cognitive effects of treatment. A second group experienced an acute decline in scores immediately after the treatment course followed by a partial rebound at follow-up, a pattern consistent with transient, treatment-related effects that fade with time. The third and most concerning group started from a low baseline and suffered a marked acute decline, entering treatment already cognitively vulnerable and deteriorating further.

Who ended up in that worst trajectory was not random. Lower baseline MoCA scores and a diagnosis of schizophrenia were associated with membership in the low-baseline, marked-decline group. This finding carries real weight for treatment planning. Patients with schizophrenia who undergo ECT, often for refractory symptoms, may represent a population in whom cognitive reserve is already diminished and in whom the additional burden of a treatment course pushes function below a critical threshold. The results support a model of risk-stratified cognitive monitoring, in which patients are assessed before treatment and assigned to different intensities of follow-up based on their baseline profile and diagnostic background, rather than receiving a uniform, one-size-fits-all check.

The study also ventured into territory that has attracted growing interest across neuropsychiatry: the role of inflammation. In exploratory analyses, the researchers examined systemic immune-inflammatory markers, including the systemic immune-inflammation index and related indices derived from routine blood counts, along with C-reactive protein, a well-known marker of systemic inflammation. Their analyses suggested that systemic immune-inflammatory burden characterized the unfavourable cognitive trajectories, and, intriguingly, that baseline CRP levels interacted with the cumulative ECT charge, the total amount of electrical stimulation a patient received over the course. In other words, the relationship between how much stimulation a patient’s brain absorbed and whether that patient developed clinician-adjudicated cognitive impairment appeared to depend on the inflammatory state of the body before treatment began.

These inflammatory findings must be read with appropriate caution, as the authors themselves frame them as exploratory, and a single cohort study cannot establish mechanism. But the underlying hypothesis is biologically plausible and resonates with a broader literature linking neuroinflammation to vulnerability of the hippocampus and other memory-critical structures. If confirmed in independent samples, the idea that inflammatory status modifies the cognitive cost of cumulative electrical stimulation could reshape how clinicians think about dosing strategies. It might eventually support the use of inexpensive blood tests, already drawn routinely in pre-ECT workups, as part of a personalized risk assessment, and it could motivate trials of anti-inflammatory or lifestyle interventions aimed at lowering inflammatory burden before an elective treatment course.

What the study delivers most concretely is a validation case for disease-specific measurement. The ECT-CI tracked score changes that the MoCA missed, discriminated better against a rigorous clinical reference standard, predicted three-month outcomes from baseline, and lent itself to trajectory-based risk stratification, all while requiring less administration time. For a procedure administered to hundreds of thousands of patients worldwide each year, the absence of a dedicated cognitive monitoring standard has been a conspicuous gap. This prospective real-world cohort, registered with the Chinese Clinical Trial Registry and conducted under ethics approval at Peking University Sixth Hospital, provides the strongest longitudinal evidence to date that filling that gap is both feasible and clinically worthwhile. The next steps, replication in larger and more diverse populations, external validation of the three-trajectory model, and prospective testing of whether risk-stratified monitoring actually improves patient outcomes, will determine whether the ECT-CI moves from promising research instrument to standard of care. For now, the message for clinicians is clear: when it comes to the cognitive price of electroconvulsive therapy, the right questions, asked with the right tool, reveal risks that general screening has been quietly missing.

Subject of Research: Longitudinal validation of the ECT-CI for monitoring cognitive impairment after electroconvulsive therapy

Article Title: Longitudinal evaluation of the ECT-CI after electroconvulsive therapy: score changes, clinical discrimination, and latent score trajectories in a prospective real-world cohort

Article References: Guo, Q., Wang, Y., Guo, L., He, X., Pu, C., Shi, C., & Shang, S. (2026). Longitudinal evaluation of the ECT-CI after electroconvulsive therapy: score changes, clinical discrimination, and latent score trajectories in a prospective real-world cohort. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08718-2

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08718-2

Keywords: electroconvulsive therapy, ECT-CI, cognitive impairment, MoCA, growth mixture modelling, prognostic discrimination, inflammation, CRP, psychiatry, neuropsychological assessment, schizophrenia, longitudinal cohort

The research team, led by Seri Lim and Joshua Ryan Smith of Vanderbilt University Medical Center, along with collaborators at Massachusetts General Hospital, Harvard Medical School, and the University of Queensland, combined a case series of five patients treated at Vanderbilt with a systematic review of the international literature. By pooling participant-level data rather than relying on study-level summaries, the investigators assembled a cohort of 27 individuals with Down syndrome regression disorder and co-occurring catatonia who had received electroconvulsive therapy. According to the authors, this represents the largest analysis conducted so far on the use of the treatment in this population.

Down syndrome itself is the most common genetic cause of intellectual disability worldwide, arising in roughly one in 800 to 1,000 live births, most often through trisomy of chromosome 21. More than 214,000 people with Down syndrome live in the United States alone. Down syndrome regression disorder, previously called Down syndrome disintegrative disorder, is a potentially life-threatening complication marked by an acute or subacute loss of previously acquired skills, cognitive decline, affective instability, and language regression. Patients may develop new-onset insomnia, psychomotor slowing, mutism, and catatonia. The underlying causes remain poorly understood, though researchers have hypothesized roles for autoimmune dysregulation, psychosocial stressors, and co-morbid psychiatric illness.

Catatonia, the condition at the heart of the new analysis, is a treatable psychomotor syndrome characterized by distinct physical examination findings such as staring, grimacing, rigidity, and mutism. It can occur across the neurodivergent spectrum and throughout the lifespan, and it carries substantial morbidity and mortality, particularly among children and adolescents. Individuals with neurodevelopmental disorders face an elevated risk of delayed diagnosis, and their catatonia may present unusually, with loss of previously acquired skills and communicative abilities that mirror the broader regression seen in Down syndrome regression disorder. Some researchers have even questioned whether catatonia is a core component of the regression disorder itself, or whether the condition belongs on the catatonia spectrum.

To quantify the effect of electroconvulsive therapy, the team relied on the Bush-Francis Catatonia Rating Scale, a 23-item clinical instrument that grades the severity of each catatonic sign, with a maximum possible score of 69. Across the combined dataset, 17 pre-treatment and 15 post-treatment scores were available from 18 patients across seven sites or studies. The mean score before treatment was 17.40, falling to 4.40 afterward. A generalized estimating equations analysis, which accounts for the clustering of patients within the same study, found a statistically significant reduction of 13.00 points, with a 95 percent confidence interval spanning from 17.70 down to 8.18 and a p-value below 0.001. In plain terms, the treatment was associated with a substantial and statistically robust easing of catatonic symptoms.

The clinical picture of the patients underscores how difficult these cases are. The 27 patients, whose average age was 20.7 years, had collectively failed dozens of medication trials before turning to electroconvulsive therapy, with a mean of 2.4 failed psychiatric medications per patient. Lorazepam, a benzodiazepine and standard first-line agent for catatonia, had been tried in two-thirds of the cohort. Selective serotonin reuptake inhibitors such as sertraline and fluoxetine, antipsychotics such as quetiapine and aripiprazole, mood stabilizers, anticonvulsants, and even the NMDA receptor antagonist memantine had all been deployed with limited success. Medical and psychiatric comorbidities were common, including hypothyroidism in more than a fifth of patients, celiac disease, autoimmune encephalitis, major depressive disorder, and autism spectrum disorder.

The technical details of the treatment at Vanderbilt offer a rare window into how electroconvulsive therapy is actually delivered in this population. All five Vanderbilt patients received bitemporal electrode placement with brief-pulse stimulation, undergoing 171 treatments in total. Anesthesia was induced with methohexital at a mean dose of 68.4 milligrams, with succinylcholine providing muscle relaxation. Electroencephalographic seizure duration averaged 60.9 seconds, and propofol was used to terminate prolonged seizures, defined as those exceeding two minutes, in 19 percent of sessions. Notably, in about 16 percent of treatments, intramuscular ketamine was required to establish intravenous access because agitation or distress prevented conventional placement, a maneuver the authors report as the first described in this population. Despite the intensity of the treatment course, no severe adverse events were documented, although all five patients had difficulty verbalizing subjective side effects because of their intellectual disability.

The findings arrive with important caveats. The sample remains small, the data were collected retrospectively, and the analysis carries an inherent bias toward positive outcomes: patients unlikely to continue receiving dozens of electroconvulsive sessions unless some benefit was observed. Reporting of treatment parameters and rating scales was inconsistent across the studies included in the systematic review, and many patients received concurrent therapies, including intravenous immunoglobulin in a third of cases, making it impossible to isolate the specific contribution of the electrical stimulation. The authors also note that eight patients in the cohort were under 18, an age group whose access to electroconvulsive therapy is restricted by state-dependent legislation in the United States, and that stigma, limited education, and provider shortages limit availability worldwide.

Even so, the study marks a turning point for a condition that has lacked any evidence-based treatment algorithm. The authors recommend that future research examine electroconvulsive therapy for catatonia in Down syndrome regression disorder prospectively, with standardized reporting of electrode placement, pulse width, seizure duration, acute and maintenance treatment schedules, and cognitive outcomes. They also call for improved screening, including telemedicine-based catatonia assessments, to speed diagnosis in a population where symptoms are easily mistaken for the regression itself. Given the significant improvement in both regression and catatonic symptoms observed, the researchers suggest that clinicians should consider electroconvulsive therapy earlier in the disease course rather than as a last resort after years of failed medication trials.

For a condition that can strip away speech, movement, and independence in a matter of months, the message of this study is quietly radical: a treatment often portrayed as barbaric may, carefully administered, give young people with Down syndrome their lives back. The evidence base is still thin, built on 27 patients and seven research sites, but the signal is strong, the treatment was well tolerated, and the alternative for many families is watching a child disappear into unresponsive silence. As the authors conclude, more rigorous research is needed, but the era of assuming nothing can be done for regression in Down syndrome may finally be coming to an end.

Subject of Research: Electroconvulsive therapy for catatonia in Down syndrome regression disorder

Article Title: Use of Electroconvulsive Therapy for Catatonia in Down Syndrome Regression Disorder: A Systematic Review, Case Series, and Analysis

Article References: Lim, S., Kang, K., Oey, E., Santoro, S., Franklin, C., Luccarelli, J., Tamargo, R., Hamilton, C., Marler, S., Adegoke, T., Wilson, J. E., & Smith, J. R. (2026). Use of Electroconvulsive Therapy for Catatonia in Down Syndrome Regression Disorder: A Systematic Review, Case Series, and Analysis. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-026-07500-3

Image Credits: AI Generated

DOI: 10.1007/s10803-026-07500-3

Keywords: Down syndrome, Down syndrome regression disorder, catatonia, electroconvulsive therapy, Bush-Francis Catatonia Rating Scale, systematic review, case series, psychiatry, neurodevelopmental disorders, regression, ketamine, Vanderbilt University Medical Center

The centerpiece of the October issue of The American Journal of Psychiatry is a special issue on neuromodulation and precision therapeutics, assembled with guest editor William McDonald, M.D., professor of psychiatry and behavioral sciences at Emory University School of Medicine. McDonald joins Ned Kalin, the journal’s editor-in-chief, on this month’s AJP Audio podcast to discuss the collection. The special issue arrives at a moment when neuromodulation, once a niche corner of psychiatry, has become one of its most active frontiers, encompassing transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and emerging techniques that promise to steer electrical activity in deep brain circuits without surgery.

One of the issue’s framing contributions describes the current wave of brain stimulation therapeutic interventions in neuropsychiatry as a Cambrian explosion, an evocative metaphor borrowed from evolutionary biology to convey the sheer diversity of approaches now proliferating. Alongside it, a second perspective article examines artificial intelligence as the computational framework for adaptive closed-loop neuromodulation in psychiatry. Closed-loop systems, which sense neural activity and adjust stimulation parameters in real time, are widely viewed as the next step beyond fixed-protocol stimulation, and the article argues that machine learning provides the mathematical machinery needed to make such adaptive control clinically reliable.

The special issue also features original clinical trials that test whether precision targeting can improve outcomes. One randomized, sham-controlled trial investigates bilateral theta-burst stimulation of dorsolateral prefrontal cortex regions for late-life depression, a population in which treatment-resistant mood disorders carry substantial disability and medical burden. A companion study reports convergent network localization of brain stimulation targets for trait anxiety, an approach that uses converging evidence about brain networks to identify where stimulation might most effectively modulate a given symptom dimension. AJP Deputy Editor Daniel Pine, M.D., highlights both studies in accompanying videos for the journal’s readership.

Two further trials push the precision theme further. The first, the CORRECT-BD trial, compares clinical and cognitive outcomes of right unilateral ultrabrief electroconvulsive therapy against magnetic seizure therapy for bipolar depression, a comparison that speaks directly to a longstanding clinical concern: preserving cognition while retaining the robust antidepressant efficacy of seizure-based treatments. The second is an individualized, connectivity-guided versus conventional targeting trial of accelerated theta-burst stimulation in depression, a randomized, double-blind, parallel-design study that asks whether personalizing stimulation targets to each patient’s brain connectivity outperforms standard coordinate-based targeting.

The issue also revisits one of the most consequential and debated studies in the field. The RECOVER trial of vagus nerve stimulation in markedly treatment-resistant depression is examined in an article on its critical findings, lessons learned, and future directions, with lead author Charles R. Conway, M.D., discussing the results on the AJP Audio podcast. Additional contributions survey precision neuromodulation with a focus on temporal interference stimulation, a technique designed to reach deep brain structures noninvasively by interfering two high-frequency fields at a targeted point. A commentary argues for advancing brain stimulation toward first-line psychiatric therapy through wearable disposable electrotherapy, while another article addresses implantable neuromodulation devices in psychiatry, weighing human fidelity and the implementation challenges that stand between promising devices and routine clinical use.

The October issue of Psychiatric Services shifts the lens from circuits to systems, publishing research on how mental health care is organized, measured, and delivered. Highlights include the Mental Wellness Tool, a brief screener designed to detect mental disorders, substance use disorders, and suicide risk in a single instrument, and a set of recommendations from a participatory policymaking symposium on emergency psychiatric evaluation of people under arrest, an area where clinical practice, law enforcement, and civil rights intersect. Other articles examine VA health care utilization among U.S. veterans through the influence of social determinants of health, and a methodological piece on suicide surveillance and Simpson’s Paradox warns that aggregating data can obscure critical patterns that appear only when populations are disaggregated.

Access and equity questions recur throughout the issue. One study documents wait times and documentation requirements for child psychiatric care across payer and facility types, quantifying the administrative friction families face when seeking help for children. Another reports on public support for state laws requiring addiction programs to offer FDA-approved medications for opioid use disorder, a finding with direct relevance to ongoing policy debates about whether treatment programs should be legally obligated to provide evidence-based pharmacotherapy. Together, these papers illustrate how service-level research complements clinical neuroscience by identifying where the system itself becomes a barrier to care.

The American Journal of Psychotherapy contributes a third perspective, centered on the human relationship at the heart of psychiatric treatment. Articles examine gender and age differences in psychotherapy use among U.S. adults with depression and anxiety, and explore the effects of psychotherapies for posttraumatic stress disorder on anger, an often-overlooked symptom in trauma treatment research. Clinical technique is addressed in a paper on the RFP-C triangle of conflict, which considers how attending to countertransference can help clinicians listen more effectively to children with disruptive behaviors. Cultural adaptation is the focus of an article on interpersonal psychotherapy in the Chinese cultural context, while a study of group acceptance and commitment therapy for adolescent anxiety reports on initial acceptability and outcomes of a group format aimed at expanding access for young patients.

Psychiatric Research and Clinical Practice rounds out the collection with translational and real-world studies. A viewpoint article considers fostering social connection, tracing progress and opportunities within the VA and beyond, a topic of growing public health interest given evidence linking isolation to morbidity. A comparative study assesses the risks of pregnancy complications in women prescribed psychostimulants or atomoxetine during pregnancy following pre-pregnancy stimulant use, addressing a population long underrepresented in psychopharmacology research. The journal also publishes a real-world effectiveness and cost-differential analysis of intranasal esketamine versus intramuscular ketamine, two rapid-acting treatments for depression whose relative value outside controlled trials remains a pressing question for clinicians and payers. Finally, a real-world pilot evaluates the collaborative care model for adults with cognitive impairment and neuropsychiatric symptoms in primary care, testing whether an integrated care framework developed for depression can extend to patients with complex neuropsychiatric needs. Journalists seeking access to the publications can contact the American Psychiatric Association press office at press@psych.org.

Subject of Research: Neuromodulation, precision therapeutics, esketamine, and mental health services research featured across APA journals

Article Title: October 2026 Issues of APA Journals feature new research on neuromodulation and precision therapeutics, esketamine, and more

Article References: October 2026 Issues of APA Journals feature new research on neuromodulation and precision therapeutics, esketamine, and more. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuromodulation, precision therapeutics, brain stimulation, esketamine, theta-burst stimulation, vagus nerve stimulation, electroconvulsive therapy, depression, psychotherapy, psychiatric services, American Psychiatric Association, mental health care

The evidence for this drift is economic as much as scientific. Drawing on workforce research by Tadmon and Olfson published in the American Journal of Psychiatry, the authors describe a profession whose practice has narrowed under financial pressure. Psychiatrists increasingly deliver brief medication-management visits rather than the psychotherapy that once defined the field, a shift driven by reimbursement structures, administrative burdens and the economics of outpatient care. Studies from Hughes and colleagues in Psychiatric Services reinforce the picture, documenting how access to psychiatrists providing talk therapy has contracted even as demand for mental health care has surged. The result is a specialty whose self-image, rooted in the integration of biological and psychological treatment, no longer matches the reality of a fifteen-minute medication check.

At the same time, an entirely new therapeutic arsenal has matured. Repetitive transcranial magnetic stimulation, now supported by accelerated protocols that can deliver a full treatment course in days rather than weeks, has moved from experimental novelty to mainstream clinical tool. Esketamine nasal spray and off-label ketamine have introduced rapid-acting pharmacological interventions that require monitored, procedure-like administration. Electroconvulsive therapy, long the most effective treatment for severe depression, continues to evolve with modern techniques such as right unilateral ultrabrief pulse stimulation. Psychedelic-assisted therapies, including psilocybin and MDMA, are advancing through late-stage clinical trials and promise to add further procedurally intensive options. Each of these treatments shares a defining feature: the psychiatrist is no longer simply prescribing a medication, but directly performing or supervising a physical intervention on the brain.

The authors argue that this convergence of forces has created an identity crisis. Professional identity, as the medical education literature from Cruess and colleagues emphasizes, is not a cosmetic matter; it shapes how clinicians see their roles, how trainees choose specialties, how institutions allocate resources and how the public understands what a profession offers. A field that defines itself around diagnostic evaluation and pharmacological management is poorly equipped to steward technologies that require procedural skill, anatomical and neuroscientific knowledge, and rigorous safety protocols. Without a coherent identity, the authors warn, psychiatry risks ceding these interventions to other specialties or to commercial actors operating outside the traditional structures of academic medicine.

Their proposed solution is interventional psychiatry, defined not as a replacement for existing psychiatric practice but as an integrative framework that unites psychiatric judgment with procedural care. The concept is deliberately broad. It encompasses neuromodulation techniques such as TMS, vagus nerve stimulation and deep brain stimulation; pharmacological interventions requiring procedural administration, including ketamine and esketamine; convulsive therapies such as ECT; and, prospectively, psychedelic-assisted treatments. What binds them together is a shared logic: the psychiatrist’s diagnostic acumen, formulation skills and longitudinal therapeutic relationship remain central, but they are now paired with hands-on technical competence and an understanding of circuit-level neuroscience.

To help clinicians and institutions think about this expanding toolkit, the paper introduces a risk–skill matrix, a conceptual map that plots interventions according to the technical skill they demand and the risk they carry to patients. The matrix serves several purposes. It clarifies which treatments can be delivered safely in routine outpatient settings and which require specialized facilities, anesthesia support or intensive monitoring. It provides a rational basis for credentialing and privileging decisions, an increasingly urgent question as TMS clinics proliferate and ketamine administration spreads into commercial practice. And it offers trainees a structured way to understand the competencies they must acquire, from basic certification in office-based neuromodulation to advanced fellowship-level training in interventional procedures.

The historical analogy the authors reach for is cardiology. In 1977, Andreas Grüntzig performed the first coronary angioplasty, an event documented in The Lancet, and in the decades that followed cardiology transformed from a largely diagnostic and pharmacological specialty into one defined by interventional procedures. That transformation did not diminish the cardiologist’s medical judgment; it amplified it, demanding deeper integration of physiology, imaging and procedural technique. The authors contend that psychiatry now stands at a comparable inflection point. Just as interventional cardiology emerged as a recognized identity within cardiology, interventional psychiatry can serve as the organizing concept for a specialty whose therapeutic reach is expanding into direct neural intervention.

The idea itself is not entirely new. As early as 2014, Williams and colleagues argued in the Journal of Clinical Psychiatry and Academic Psychiatry for the development of interventional psychiatry fellowships and training pathways, and subsequent work by Trapp and Williams, along with a 2021 review in the American Journal of Psychiatry led by McIntyre, helped build the scientific case for circuit-based therapeutics in psychiatry. What the new Comment adds is a comprehensive professional framework: a definition, a conceptual structure for classifying interventions, and a roadmap for how training, credentialing and practice organization should evolve. The authors, who span academic centers including Yale, the University of California San Diego, Oxford and Toronto as well as clinical practice, frame the proposal as an evolutionary step rather than a rupture with psychiatric tradition.

The implications for training are among the most concrete. Current residency requirements, governed by the Accreditation Council for Graduate Medical Education, provide limited structured exposure to procedural techniques, and the authors suggest that the field must decide whether interventional competencies should be embedded in core residency training or developed through dedicated fellowships. Either path carries consequences for workforce planning. If interventional psychiatry becomes a recognized subspecialty, it could attract trainees drawn to the technical and neuroscientific dimensions of mental health care, potentially strengthening recruitment into a specialty that has struggled to meet demand. It could also reshape the economics of practice, since procedural services are typically reimbursed differently from brief medication visits, potentially relieving some of the financial pressures that pushed psychotherapy out of psychiatric practice in the first place.

The authors are candid that the framework raises difficult questions. Boundaries must be drawn carefully to avoid implying that interventional techniques should replace psychotherapy or psychosocial care, which remain essential components of treatment for many conditions. Equity of access is a serious concern, since advanced interventions are concentrated in urban and well-resourced settings, and the authors’ own disclosed ties to industry and clinical enterprises underline the commercial stakes involved in how the field develops. Yet their central claim stands on solid ground: the tools of psychiatry have changed faster than its identity, and a profession that treats the brain with electricity, magnetic fields and rapidly acting molecules needs a name and a structure that reflect that reality. Interventional psychiatry, they argue, is that name, and the coming years will determine whether the profession embraces the framework deliberately or continues to evolve by accident.

Subject of Research: A proposed professional framework defining interventional psychiatry amid the growth of procedural mental health treatments

Article Title: Defining interventional psychiatry: a framework for professional identity and practice evolution

Article References: Sauvé, W. M., Insel, T. R., Albright, B. B., Koo, M., Berman, R. M., Stahl, S., Manji, H. K., McIntyre, R. S., & Qian, J. J. (2026). Defining interventional psychiatry: a framework for professional identity and practice evolution. Nature Mental Health. https://doi.org/10.1038/s44220-026-00708-3

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00708-3

Keywords: interventional psychiatry, psychiatry, neuromodulation, transcranial magnetic stimulation, electroconvulsive therapy, ketamine, esketamine, psychedelic therapy, professional identity, medical training, Nature Mental Health, mental health care

Rather than treating changes as isolated region-by-region effects, the team used network localization to identify where structural and functional alterations tend to emerge within interconnected circuits. This approach frames the brain as a dynamic system, where symptoms and recovery may reflect coordinated shifts across networks rather than single “hot spots.”

The study integrates imaging-based measures of structural connectivity and functional patterns, allowing the investigators to localize ECT-related modifications within specific network neighborhoods. By aligning multiple modalities, the researchers aimed to determine whether structural reorganization and functional changes converge on shared circuit locations, potentially offering a more mechanistic account of clinical benefit.

Such multimodal convergence matters because depression involves widespread disruptions spanning large-scale networks, including systems associated with mood regulation, cognitive control, and self-referential processing. If ECT can repeatedly target the same circuit hubs or communication pathways, that would suggest a route from treatment dose to neural recalibration.

The authors describe network localization as a way to reduce ambiguity common in post-treatment neuroimaging. Instead of asking where the brain “changes,” the analysis asks where in the network topology those changes are most likely to concentrate—information that could improve interpretation across studies and patient variability.

Importantly, the work highlights that ECT-induced alterations may not be uniform across the brain. The findings suggest that specific network substructures could act as anchors for both structural remodeling and functional dynamics, which may relate to symptom improvement.

The study’s results also imply that monitoring therapeutic impact might benefit from circuit-level biomarkers. If reliable network signatures can be detected after treatment, they could support stratification of patients or guide optimization of stimulation parameters.

Finally, by linking structural and functional localization within the same network framework, the research advances a systems-level view of how ECT may “reset” dysregulated communication in depression. As clinical neuroimaging moves toward network neuroscience, these methods may sharpen how future trials evaluate mechanistic endpoints.

Subject of Research: Brain structural and functional alterations in depression induced by electroconvulsive therapy (ECT).

Article Title: Network localization of brain structural and functional alterations induced by electroconvulsive therapy for depression.

Article References: Yao, S., Zhu, DM., Zhu, H. et al. Network localization of brain structural and functional alterations induced by electroconvulsive therapy for depression. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04308-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04308-8

Electroconvulsive therapy, a psychiatric treatment utilizing brief electrical currents passed through the brain to induce seizures, has long been a mainstay for severe depression, bipolar disorder, and other mental health conditions that resist traditional pharmacotherapies. While its efficacy is well documented, the precise neural mechanisms underlying its therapeutic benefits and side effects remain only partially understood. The novel observation of spreading depolarization waves following induced seizures adds a crucial piece to this complex puzzle, potentially bridging gaps in our prior knowledge of postictal brain states.

Spreading depolarization is a wave-like phenomenon characterized by a massive, transient disruption of neuronal membrane potentials, leading to a temporary silencing of brain activity as ions flow abnormally across cell membranes. It has been extensively studied in contexts such as migraine auras, stroke, traumatic brain injury, and epilepsy. However, its presence and role following ECT-induced seizures were previously unexplored territory. This study’s findings suggest that such depolarization waves are an intrinsic neural signature of the postictal state, contributing to the transient neurological symptoms experienced after ECT sessions.

The investigation employed cutting-edge electrophysiological recording techniques that captured brain activity with exquisite temporal precision in both animal models and human patients. In mice subjected to controlled electroconvulsive shocks, researchers observed a distinct spreading depolarization propagating across vast cortical territories shortly after the seizure event concluded. Paralleling these preclinical insights, intracranial recordings in patients treated with ECT revealed similar postictal spreading depolarizations, marking this as a conserved neurophysiological process across species.

These findings have profound implications for interpreting the clinical aftermath of ECT. The postictal period—characterized by altered consciousness, confusion, and cognitive disturbances—has long been noted but poorly understood mechanistically. The spreading depolarization wave may serve as a neurobiological substrate for this transient impairment, providing a target for potential interventions aiming to improve recovery and minimize side effects. Moreover, understanding how this wave modulates neuronal networks could unlock new strategies to harness or refine ECT’s therapeutic effects.

From a technical standpoint, the researchers meticulously mapped the spatial and temporal dynamics of spreading depolarization waves, uncovering that these waves propagate at a speed consistent with other pathological brain events but uniquely tailored to the context of ECT-induced seizure activity. The depolarization was found to silencing neural circuits transiently, potentially resetting overactive or dysfunctional networks implicated in mood disorders. This introduces a compelling framework by which ECT may exert long-term mood-stabilizing effects by orchestrating large-scale neural reorganization through these waves.

Furthermore, the study delves into the molecular underpinnings of this phenomenon. Ion fluxes, especially of potassium and calcium, along with metabolic changes disrupting neuronal homeostasis, were implicated in wave generation and propagation. This biochemical cascade may simultaneously trigger neuroprotective mechanisms and transient metabolic stress, balancing treatment efficacy with risk of adverse effects. Future research targeting these molecular pathways could pave the way for adjunctive therapies that enhance ECT safety and tolerability.

The translational nature of the research—from mouse models to human patients—underscores its significance. Animal studies allowed unparalleled access to invasive electrophysiological data, while human intracranial recordings validated the phenomenon’s clinical relevance, bridging bench to bedside. This dual approach strengthens confidence in the generalizability of findings and invites further exploration into personalized ECT protocols that account for individual neural susceptibilities to spreading depolarization.

Intriguingly, this work also intersects with broader debates regarding brain excitability and resilience. The spreading depolarization wave, while transient and reversible, may represent a double-edged sword: a necessary reset mechanism for dysfunctional circuitry but also a potential trigger for deleterious outcomes in vulnerable individuals. Clarifying these dual roles promises to refine patient screening and post-treatment monitoring, potentially enabling clinicians to anticipate and mitigate risks such as prolonged recovery or cognitive side effects.

Moreover, the study’s methodological innovations, including simultaneous high-density electrocorticography and innovative data analytics, set new standards for neurophysiological research in clinical settings. The high spatiotemporal resolution recordings allowed researchers to discern subtle neural events previously obscured in standard EEG or imaging modalities. This technological leap forward heralds a new era where intricate brain dynamics underlying psychiatric treatments can be deciphered in vivo with unprecedented clarity.

Looking ahead, these insights could catalyze a renaissance in ECT research and practice. A deeper grasp of spreading depolarization waves may inspire novel therapeutic paradigms that optimize seizure induction parameters or integrate neuroprotective agents to enhance patient outcomes. Moreover, this line of inquiry could stimulate investigations into spreading depolarizations’ roles in other neuropsychiatric interventions, potentially unveiling universal mechanisms of brain plasticity and repair.

While the study opens the door to exciting possibilities, it also raises important questions demanding further exploration. For example, how do individual differences in brain anatomy, disease state, or genetic makeup influence the characteristics of postictal spreading depolarization? Could variations in wave dynamics predict therapeutic response or side effect profiles? Answering these questions will be vital in translating these fundamental discoveries into clinical innovations that truly benefit patients.

In addition, integrating these findings with neuroimaging biomarkers and cognitive assessments may help delineate the complex relationship between spreading depolarization waves and behavioral outcomes. Such multidisciplinary approaches could refine prognostic models and personalize intervention strategies, moving toward precision psychiatry where treatments are tailored to each patient’s neural signature and clinical needs.

This pioneering work by Rosenthal, Majeski, Somarowthu, et al. stands as a testament to the power of interdisciplinary collaboration in unraveling the brain’s mysteries. By melding neurophysiology, psychiatry, and cutting-edge technology, the team has illuminated a hidden dimension of ECT’s impact on the brain, setting the stage for transformative advances in neuroscience and mental health care. As the scientific community digests these revelations, the ripples of this discovery will likely extend far beyond the realm of ECT, enriching our broader understanding of brain function and dysfunction.

Ultimately, the identification of a postictal wave of spreading depolarization challenges long-held assumptions and provides a new conceptual lens through which to view the neurobiological consequences of seizure-based therapies. It underscores the brain’s remarkable capacity for both disruption and restoration, offering hope that harnessing such mechanisms can pave the way for safer, more effective treatments for devastating psychiatric disorders. The future of mental health treatment may well be shaped by these waves of depolarization rippling silently beneath the surface, guiding clinicians toward more enlightened interventions.

As research continues to probe the depths of these complex neural phenomena, patients and clinicians alike can look forward to a new era wherein electroconvulsive therapy is not just a blunt instrument but a finely tuned neuroscientific approach grounded in detailed knowledge of brain dynamics. Through such rigorous scientific inquiry, the mysteries of the mind may be gradually unveiled, delivering breakthroughs that resonate long after the seizure subsides.

Subject of Research: Electroconvulsive therapy-induced spreading depolarization waves in the brain of mice and humans.

Article Title: Electroconvulsive therapy generates a postictal wave of spreading depolarization in mice and humans.

Article References:
Rosenthal, Z.P., Majeski, J.B., Somarowthu, A. et al. Electroconvulsive therapy generates a postictal wave of spreading depolarization in mice and humans. Nat Commun 16, 4619 (2025). https://doi.org/10.1038/s41467-025-59900-1

Image Credits: AI Generated